References
- Patel R, Pandya AG, Sikirica V, et al. Prevalence of vitiligo among children and adolescents in the United States. Dermatology. 2023;239(2):1–3. doi: 10.1159/000528180.
- Mastacouris N, Strunk A, Garg A. Incidence and prevalence of diagnosed vitiligo according to race and ethnicity, age, and sex in the US. JAMA Dermatol. 2023;159(9):986–990. doi: 10.1001/jamadermatol.2023.2162.
- Searle T, Al-Niaimi F, Ali FR. Vitiligo: an update on systemic treatments. Clin Exp Dermatol. 2021;46(2):248–258. doi: 10.1111/ced.14435.
- Gianfaldoni S, Wollina U, Tchernev G, et al. Vitiligo in children: a review of conventional treatments. Open Access Maced J Med Sci. 2018;6(1):213–217. doi: 10.3889/oamjms.2018.054.
- Rosmarin D, Soliman AM, Li C. Real-World treatment patterns in patients with vitiligo in the United States. Dermatol Ther (Heidelb). 2023;13(9):2079–2091. doi: 10.1007/s13555-023-00983-3.
- NAMCS/NHAMCS - HIPAA Privacy Rule Questions and Answers for NAMCS. Published 2019 Oct 28. https://www.cdc.gov/nchs/ahcd/namcs_hipaa_privacy.htm.
- Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001;33(4):289–294. doi: 10.1097/00004836-200110000-00006.
- Pathak GN, Chandy RJ, Shah R, et al. The pharmacist’s role in dermatology: patient medication adherence. J Dermatol. 2023;50(9):1099–1107. doi: 10.1111/1346-8138.16895.